

Julio Montaner

Julio S. G. Montaner, OC, OBC, MD, DSc (Hon), FRCPC, FCCP, FACP, FRSC
Killam Professor of Medicine,
Faculty of Medicine, University of British Columbia;
UBC and St. Paul's Foundation Chair in AIDS Research;
Executive Director and Physician-in-Chief, BC Centre for Excellence in HIV/AIDS,
Providence Health Care;
Head, HIV/AIDS Program, St. Paul's Hospital, Providence Health Care;
Past-President, International AIDS Society (2008-2010);
UNAIDS Special Advisor on HIV Therapeutics (2014-2017).
Vancouver, BC, Canada

Biography:

Dr. Julio Montaner - UBC and St. Paul's Foundation Chair in AIDS Research. Dr. Montaner is a UBC-Killam Professor of Medicine, the Executive Director and Physician-in-Chief of the BC Centre for Excellence in HIV/AIDS, and the UNAIDS Special Advisor on HIV Therapeutics (2014-2017). Dr. Montaner played a key role in the development and implementation of Highly Active Antiretroviral Therapy (HAART) as the modern standard of care for HIV disease. He then pioneered Treatment as Prevention® (TasP®) using HAART to simultaneously stop progression to AIDS and death, and HIV transmission. Based on his TasP® strategy, he proposed the 90-90-90 Target that has now been formally adopted by the UN to accelerate the global control of HIV/AIDS.

Title of Plenary Lecture:

Social Justice, personally and globally - do health care institutions matter?

Abstract:

HIV-Treatment as Prevention®
A patient centered strategy to end HIV/AIDS

HIV-Treatment as Prevention® (TasP®) pioneered by the BC Centre for Excellence in HIV/AIDS (BC-CfE) is a strategy aimed to maximize the impact of highly active antiretroviral therapy (HAART) at the individual and public health level to achieve HIV Disease Elimination and promote Health Care Sustainability. This approach is based on our recognition that HAART is highly effective in preventing: 1) progression to AIDS, 2) premature death, and 3) HIV transmission. Thus, optimizing and facilitating access to the best available standard of care addresses the key individual concerns (i.e.: disease progression and premature death), while stopping HIV transmission, in a cost saving fashion. This approach has allowed British Columbia to virtually control its HIV/AIDS epidemic, and in doing so, to offer the world a road map for global control of HIV/AIDS. Our TasP® strategy and the related 90-90-90 Target have now been adopted formally by the United Nations for the global control of HIV/AIDS by 2030, as part of the UN Sustainable Development Goals agenda.